Results 121 to 130 of about 55,598 (218)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

An integrated framework of TOE, RBV, and institutional theory for understanding blockchain adoption in Egyptian public hospitals. [PDF]

Sci Rep
Abdou A, El-Demerdash BE, Mazen S, Darwish NR.   +3 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Exploring Healthcare Engagement Among Young Mothers and Their Children in Southern New Jersey: A Descriptive Survey Study. [PDF]

Health Sci Rep
Jin J, Jones MC, Vaughn NA, Angelone DJ, Wallace LC, Charles D, Yucel E.   +6 more
europepmc   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Identifying clinical and lifestyle factor mediators of the association between socioeconomic status and colorectal cancer mortality. [PDF]

SSM Popul Health
Lawler TP, Ogunmuyiwa O, Khatri RA, Steinwandel MD, Gangnon RE, Shrubsole MJ, Warren Andersen S.   +6 more
europepmc   +1 more source

Environmental impact of antidepressants: Is a new prescription framework possible?

British Journal of Clinical Pharmacology, EarlyView.
Aims Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing
Matilde Bianconi, Valentina Giunchi, Michael Thiede, Elisa Sangiorgi, Marco Menchetti, Elisabetta Poluzzi   +5 more
wiley   +1 more source

Understanding mobile portal app use: a theoretical extension of unified theory of acceptance and use of technology (UTAUT). [PDF]

Mhealth
Park T, Sung E, Kim B, Lee J, Yun J.
europepmc   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Commentary: Autism screening and diagnosis in children with congenital heart disease. [PDF]

Front Pediatr
Kamal M.
europepmc   +1 more source